Evidence map›Paper›PMID 23380371›Full record

ReviewSteroids2013

Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

Melanie J Grubisha, Donald B DeFranco

Open access · greenAbstract readReview
In one paragraph

Review in Steroids, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. The role of estrogen receptor β in prostate cancer.Molecular medicine (Cambridge, Mass.) · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Melanie J GrubishaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, 3051 Fifth Avenue, Pittsburgh, PA 15260, USA. grubisha.melanie@medstudent.pitt.edu
Donald B DeFranco
University of Pittsburgh · US

Funding

Intracellular Mechanisms of Glucocorticoid ActionR01DK078394 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEFRANCO, DONALD B · 2007 to 2011
$1.5M
NIDDK NIH HHS R01 DK078394
6 · The paper itself

Abstract

Androgen receptor (AR) signaling is essential for the initial development and progression of prostate cancer (PCa) as well as the growth and survival of castration-resistant tumors. However, AR action may be opposed by estrogen receptor beta (ERß) that responds to androgen metabolites produced in the prostate. The balance between the activity of these two receptors is not only influenced by the steroidogenic capacity of the prostatic microenvironment but also by its redox status and local paracrine signals such as transforming growth factor-beta (TGF-ß). In this review, we highlight the studies that revealed select roles for AR and ERß in distinct compartments of the prostate cancer microenvironment. We also discuss new work that identified stromal-epithelial crosstalk through TGF-ß1 signaling that drives the production of reactive oxygen species in stromal cells thereby selectively limiting the anti-tumor activity of ERß in cancer cells. Therefore, any new therapeutic approaches that seek to limit AR but enhance ERß activity in PCa, must take into account potential adaptive changes in the tumor microenvironment that utilize paracrine signals and altered redox balance to divert local androgen metabolites towards AR at the expense of ERß.

Indexed as

Paracrine CommunicationSignal TransductionTumor MicroenvironmentEndocrine SystemEstrogen Receptor betaHumansMaleOxidation-ReductionProstatic NeoplasmsReceptors, AndrogenEstrogen Receptor betaReceptors, Androgen

Identifiers

PMID23380371
PMCPMC3644803
OpenAlexW2000170315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.